Format

Send to

Choose Destination
Immunity. 2006 Mar;24(3):233-8.

CTLA4Ig: bridging the basic immunology with clinical application.

Author information

1
Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA. jbluest@immunetolerance.org

Abstract

After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.

PMID:
16546089
DOI:
10.1016/j.immuni.2006.03.001
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center